These findings support the adequacy of the ICAM-1-/-NOD model and set the stage for subsequent studies directed at identifying prognostic markers of the highly heterogenous IVIg treatment response in CIDP. Here, ICAM1 is linked to chronic inflammatory demyelinating polyradiculoneuropathy.